Fresenius Medical Care FME.DE
What does Fresenius Medical Care do?
Fresenius Medical Care is a globally active provider of dialysis services and related products for people with chronic kidney disease. The core of the business is the operation of a large network of outpatient dialysis clinics where patients are treated regularly. In addition, the company offers laboratory services, diagnostics, patient care and dialysis services on behalf of hospitals, particularly in the US.
The company is divided into the Care Delivery and Care Enablement segments. Care Delivery covers patient treatment, while Care Enablement covers the development, manufacture and distribution of dialysis machines, dialyzers, consumables and other healthcare products. Its customers are patients, payers such as government and private insurers, as well as hospitals and other dialysis providers. Through the combination of treatment and in-house manufacturing, the company is among the world's leading providers in the dialysis market, which is shaped by a few large competitors.
Score profile
Rank vs. Medical Care Facilities (21 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.
Metrics compared with the industry
On profitability and quality, Fresenius Medical Care ranks below average in the group Medical Care Facilities (3.7/10). On growth, the company ranks in the bottom fifth in the group Medical Care Facilities (1.0/10). On valuation (higher = cheaper), the stock ranks among the best in the group Medical Care Facilities (8.0/10). On financial strength, Fresenius Medical Care ranks in the middle in the group Medical Care Facilities (4.8/10).
| Metric | Stock | Group median | Ranking |
|---|---|---|---|
| Forward P/E | 10.5x | 16.2x | better than 82 % |
| Trailing P/E | 13.5x | 19.7x | better than 81 % |
| PEG ratio | 1.0x | 1.4x | better than 68 % |
| EV/EBITDA | 7.9x | 12.3x | better than 83 % |
| Price/sales | 0.5x | 1.3x | better than 88 % |
| Price/book | 0.8x | 3.2x | better than 97 % |
| Revenue growth | 1.1% | 6.5% | better than 7 % |
| Earnings growth | -35.4% | 6.5% | better than 13 % |
| Gross margin | 26.5% | 29.9% | better than 40 % |
| Operating margin | 10.1% | 10.1% | better than 50 % |
| Net margin | 4.2% | 6.6% | better than 31 % |
| Return on equity | 7.8% | 15.4% | better than 26 % |
| Debt/equity | 79.3% | 78.7% | better than 45 % |
| Current ratio | 1.0x | 1.4x | better than 7 % |
| Free cash flow yield | 14.3% | 3.8% | better than 93 % |
| Dividend yield | 3.7% | 0.6% | – |
| Payout ratio | 50.0% | 12.5% | – |
| Beta | 0.79 | 0.77 | – |
Valuation: what is Fresenius Medical Care worth?
Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Fresenius Medical Care a model range of 62.08 EUR to 93.91 EUR per share.
17 analysts, average rating “Hold”, average price target 39.68 EUR (−1.1%).
The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.
What the business depends on
- The number of dialysis patients grows structurally with population aging and the spread of diabetes and high blood pressure.
- Reimbursement rates and the payer mix of government and private payers largely determine the earnings power of treatments.
- Vertical integration of clinic operations and in-house production of machines and consumables creates economies of scale and stable demand.
Risks
- Changes to reimbursement systems and healthcare policy, especially in the US, can significantly weigh on treatment margins.
- Staff shortages and rising wage costs in the clinics increase cost pressure, as the business is highly labor-intensive.
- New therapies for kidney disease or diabetes could, over the long term, affect the number of dialysis patients and demand for treatment.
What to look for with Fresenius Medical Care
The operating margin in the Care Delivery segment is particularly informative because it shows how well reimbursement, treatment volume and personnel costs work together.